CA3163190A1 - Systemes et procedes d'analyse d'image basee sur l'intelligence artificielle pour la detection et la caracterisation de lesions - Google Patents
Systemes et procedes d'analyse d'image basee sur l'intelligence artificielle pour la detection et la caracterisation de lesionsInfo
- Publication number
- CA3163190A1 CA3163190A1 CA3163190A CA3163190A CA3163190A1 CA 3163190 A1 CA3163190 A1 CA 3163190A1 CA 3163190 A CA3163190 A CA 3163190A CA 3163190 A CA3163190 A CA 3163190A CA 3163190 A1 CA3163190 A1 CA 3163190A1
- Authority
- CA
- Canada
- Prior art keywords
- hotspot
- processor
- map
- volume
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003902 lesion Effects 0.000 title claims abstract description 407
- 238000000034 method Methods 0.000 title claims abstract description 291
- 238000001514 detection method Methods 0.000 title claims abstract description 68
- 238000013473 artificial intelligence Methods 0.000 title abstract description 20
- 238000012512 characterization method Methods 0.000 title abstract description 6
- 238000010191 image analysis Methods 0.000 title description 6
- 230000011218 segmentation Effects 0.000 claims abstract description 346
- 238000010801 machine learning Methods 0.000 claims abstract description 318
- 238000013459 approach Methods 0.000 claims abstract description 89
- 238000002603 single-photon emission computed tomography Methods 0.000 claims abstract description 26
- 210000001519 tissue Anatomy 0.000 claims description 200
- 210000004185 liver Anatomy 0.000 claims description 147
- 210000002307 prostate Anatomy 0.000 claims description 130
- 210000000988 bone and bone Anatomy 0.000 claims description 120
- 210000000056 organ Anatomy 0.000 claims description 120
- 210000000709 aorta Anatomy 0.000 claims description 113
- 238000003384 imaging method Methods 0.000 claims description 92
- 238000012545 processing Methods 0.000 claims description 89
- 230000006870 function Effects 0.000 claims description 81
- 230000001629 suppression Effects 0.000 claims description 71
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 65
- 210000002751 lymph Anatomy 0.000 claims description 65
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 64
- 239000012217 radiopharmaceutical Substances 0.000 claims description 63
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 63
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 63
- 210000004872 soft tissue Anatomy 0.000 claims description 62
- 230000008569 process Effects 0.000 claims description 59
- 230000015654 memory Effects 0.000 claims description 54
- 238000012552 review Methods 0.000 claims description 47
- 230000003044 adaptive effect Effects 0.000 claims description 46
- 239000011230 binding agent Substances 0.000 claims description 43
- 238000004422 calculation algorithm Methods 0.000 claims description 38
- 238000013528 artificial neural network Methods 0.000 claims description 34
- 210000003484 anatomy Anatomy 0.000 claims description 33
- 210000001165 lymph node Anatomy 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 238000002372 labelling Methods 0.000 claims description 28
- 210000003734 kidney Anatomy 0.000 claims description 25
- 230000002452 interceptive effect Effects 0.000 claims description 22
- 238000009877 rendering Methods 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 9
- 238000003709 image segmentation Methods 0.000 claims description 8
- OLWVRJUNLXQDSP-RYUDHWBXSA-N (2s)-2-[[(1s)-1-carboxy-5-[(6-fluoropyridine-3-carbonyl)amino]pentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)C1=CC=C(F)N=C1 OLWVRJUNLXQDSP-RYUDHWBXSA-N 0.000 claims description 7
- -1 225m Chemical compound 0.000 claims description 6
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- QJUIUFGOTBRHKP-LQJZCPKCSA-N (2s)-2-[[(1s)-1-carboxy-5-[6-[3-[3-[[2-[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]methyl]-4-hydroxyphenyl]propanoylamino]hexanoylamino]pentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)CCCCCNC(=O)CCC1=CC=C(O)C(CN(CCN(CC(O)=O)CC=2C(=CC=C(CCC(O)=O)C=2)O)CC(O)=O)=C1 QJUIUFGOTBRHKP-LQJZCPKCSA-N 0.000 claims 2
- 238000002600 positron emission tomography Methods 0.000 abstract description 131
- 238000009206 nuclear medicine Methods 0.000 abstract description 39
- 206010028980 Neoplasm Diseases 0.000 abstract description 25
- 201000010099 disease Diseases 0.000 abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 21
- 238000004458 analytical method Methods 0.000 abstract description 19
- 238000002591 computed tomography Methods 0.000 description 94
- 210000004369 blood Anatomy 0.000 description 40
- 239000008280 blood Substances 0.000 description 40
- 238000010586 diagram Methods 0.000 description 31
- 210000003932 urinary bladder Anatomy 0.000 description 26
- 238000004891 communication Methods 0.000 description 22
- 230000005855 radiation Effects 0.000 description 20
- 150000003839 salts Chemical class 0.000 description 20
- 239000000700 radioactive tracer Substances 0.000 description 17
- 238000012549 training Methods 0.000 description 15
- 238000009826 distribution Methods 0.000 description 13
- 229910052751 metal Inorganic materials 0.000 description 13
- 239000002184 metal Substances 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- 238000004364 calculation method Methods 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000001788 irregular Effects 0.000 description 12
- 238000003908 quality control method Methods 0.000 description 12
- 238000013527 convolutional neural network Methods 0.000 description 11
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 10
- 239000010949 copper Substances 0.000 description 10
- 206010027476 Metastases Diseases 0.000 description 9
- 238000012879 PET imaging Methods 0.000 description 9
- 230000003187 abdominal effect Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 206010061289 metastatic neoplasm Diseases 0.000 description 9
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 9
- 210000000115 thoracic cavity Anatomy 0.000 description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000009401 metastasis Effects 0.000 description 8
- 238000012805 post-processing Methods 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 238000002595 magnetic resonance imaging Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- 101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 6
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 6
- 238000007469 bone scintigraphy Methods 0.000 description 6
- 238000004590 computer program Methods 0.000 description 6
- 239000012216 imaging agent Substances 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 5
- 229910052765 Lutetium Inorganic materials 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910052733 gallium Inorganic materials 0.000 description 5
- 229910052738 indium Inorganic materials 0.000 description 5
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 5
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000004445 quantitative analysis Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 229910052702 rhenium Inorganic materials 0.000 description 5
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 5
- 229940056501 technetium 99m Drugs 0.000 description 5
- 229910052727 yttrium Inorganic materials 0.000 description 5
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 5
- 206010061728 Bone lesion Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- XOJYSFPEJAILJZ-LCERUKBVSA-M (2s)-2-[[(1s)-4-[[(1s)-5-[bis[[1-[2-[bis(carboxymethyl)amino]-2-oxoethyl]imidazol-2-yl]methyl]amino]-1-carboxypentyl]amino]-1-carboxy-4-oxobutyl]carbamoylamino]pentanedioic acid;methanone;technetium-99(4+);chloride Chemical compound [Cl-].[99Tc+4].O=[CH-].O=[CH-].O=[CH-].N=1C=CN(CC(=O)N(CC(O)=O)CC(O)=O)C=1CN(CCCC[C@H](NC(=O)CC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(O)=O)C(O)=O)C(O)=O)CC1=NC=CN1CC(=O)N(CC(O)=O)CC(O)=O XOJYSFPEJAILJZ-LCERUKBVSA-M 0.000 description 3
- 241000489861 Maximus Species 0.000 description 3
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000003109 clavicle Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 238000011471 prostatectomy Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229910052713 technetium Inorganic materials 0.000 description 3
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- IDTMSHGCAZPVLC-STUNTBJNSA-N (2s)-2-[[(1r)-1-carboxy-2-[(4-fluoranylphenyl)methylsulfanyl]ethyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CSCC1=CC=C([18F])C=C1 IDTMSHGCAZPVLC-STUNTBJNSA-N 0.000 description 2
- 108010083158 PSMA-1007 Proteins 0.000 description 2
- 108010037516 PSMA-617 Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000007321 biological mechanism Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 210000001981 hip bone Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000007620 mathematical function Methods 0.000 description 2
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 229940102859 methylene diphosphonate Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000003681 parotid gland Anatomy 0.000 description 2
- 238000011472 radical prostatectomy Methods 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000001991 scapula Anatomy 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- JBHPLHATEXGMQR-LFWIOBPJSA-N vipivotide tetraxetan Chemical compound OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](CC1=CC=C2C=CC=CC2=C1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC1)C(O)=O)C(O)=O JBHPLHATEXGMQR-LFWIOBPJSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- FIHVIDKDARACGD-VABKMULXSA-N (2s)-2-[[(1s)-4-[[(1s)-5-[bis[[1-[2-[bis(carboxymethyl)amino]-2-oxoethyl]imidazol-2-yl]methyl]amino]-1-carboxypentyl]amino]-1-carboxy-4-oxobutyl]carbamoylamino]pentanedioic acid Chemical compound N=1C=CN(CC(=O)N(CC(O)=O)CC(O)=O)C=1CN(CCCC[C@H](NC(=O)CC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(O)=O)C(O)=O)C(O)=O)CC1=NC=CN1CC(=O)N(CC(O)=O)CC(O)=O FIHVIDKDARACGD-VABKMULXSA-N 0.000 description 1
- 108010066465 177Lu-PSMA-617 Proteins 0.000 description 1
- RSTDSVVLNYFDHY-IOCOTODDSA-K 2-[4-[2-[[4-[[(2S)-1-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]cyclohexyl]methylamino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate lutetium-177(3+) Chemical compound [177Lu+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)C1CCC(CNC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)CC1)C(O)=O)C(O)=O RSTDSVVLNYFDHY-IOCOTODDSA-K 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000004883 computer application Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000013135 deep learning Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- AEBYHKKMCWUMKX-LNTZDJBBSA-K gallium (68Ga) gozetotide Chemical compound [68Ga+3].OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)CCCCCNC(=O)CCC1=CC=C(O)C(CN(CCN(CC([O-])=O)CC=2C(=CC=C(CCC([O-])=O)C=2)O)CC([O-])=O)=C1 AEBYHKKMCWUMKX-LNTZDJBBSA-K 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000046689 human FOLH1 Human genes 0.000 description 1
- 238000003711 image thresholding Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/64—Three-dimensional objects
- G06V20/653—Three-dimensional objects by matching three-dimensional models, e.g. conformal mapping of Riemann surfaces
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/25—Fusion techniques
- G06F18/251—Fusion techniques of input or preprocessed data
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/25—Fusion techniques
- G06F18/253—Fusion techniques of extracted features
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/10—Segmentation; Edge detection
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V10/00—Arrangements for image or video recognition or understanding
- G06V10/70—Arrangements for image or video recognition or understanding using pattern recognition or machine learning
- G06V10/77—Processing image or video features in feature spaces; using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]; Blind source separation
- G06V10/80—Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
- G06V10/803—Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level of input or preprocessed data
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V10/00—Arrangements for image or video recognition or understanding
- G06V10/70—Arrangements for image or video recognition or understanding using pattern recognition or machine learning
- G06V10/77—Processing image or video features in feature spaces; using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]; Blind source separation
- G06V10/80—Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
- G06V10/806—Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level of extracted features
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V10/00—Arrangements for image or video recognition or understanding
- G06V10/70—Arrangements for image or video recognition or understanding using pattern recognition or machine learning
- G06V10/82—Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
- G06V20/698—Matching; Classification
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10072—Tomographic images
- G06T2207/10104—Positron emission tomography [PET]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10072—Tomographic images
- G06T2207/10108—Single photon emission computed tomography [SPECT]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/20—Special algorithmic details
- G06T2207/20081—Training; Learning
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/20—Special algorithmic details
- G06T2207/20084—Artificial neural networks [ANN]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V2201/00—Indexing scheme relating to image or video recognition or understanding
- G06V2201/03—Recognition of patterns in medical or anatomical images
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V2201/00—Indexing scheme relating to image or video recognition or understanding
- G06V2201/03—Recognition of patterns in medical or anatomical images
- G06V2201/032—Recognition of patterns in medical or anatomical images of protuberances, polyps nodules, etc.
Landscapes
- Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Software Systems (AREA)
- Multimedia (AREA)
- Evolutionary Computation (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Artificial Intelligence (AREA)
- Medical Informatics (AREA)
- Data Mining & Analysis (AREA)
- Computing Systems (AREA)
- Life Sciences & Earth Sciences (AREA)
- Databases & Information Systems (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mathematical Physics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Quality & Reliability (AREA)
- Image Analysis (AREA)
- Image Processing (AREA)
- Nuclear Medicine (AREA)
Abstract
L'invention concerne des systèmes et des procédés qui permettent une détection et une caractérisation améliorées de lésions chez un sujet par analyse automatisée d'images médicales nucléaires, telles que des images de tomographie par émission de positrons (TEP) et de tomographie par émission de simples photons (TESP). En particulier, dans certains modes de réalisation, les approches décrites dans la description tirent profit de l'intelligence artificielle (IA) pour détecter des régions d'images médicales nucléaires 3D correspondant à des points chauds qui représentent des lésions cancéreuses potentielles chez le sujet. Les modules d'apprentissage automatique peuvent être utilisés non seulement pour détecter la présence et les emplacements de telles régions dans une image, mais également pour segmenter la région correspondant à la lésion et/ou pour classifier de tels points chauds sur la base de la probabilité pour qu'ils indiquent une véritable lésion cancéreuse sous-jacente. Lesdites détection, segmentation et classification de lésion basées sur l'IA peuvent fournir une base pour une caractérisation supplémentaire de lésions, une charge tumorale globale et une estimation de la gravité et du risque de maladie.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063048436P | 2020-07-06 | 2020-07-06 | |
| US63/048,436 | 2020-07-06 | ||
| US17/008,411 US11721428B2 (en) | 2020-07-06 | 2020-08-31 | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
| US17/008,411 | 2020-08-31 | ||
| US202063127666P | 2020-12-18 | 2020-12-18 | |
| US63/127,666 | 2020-12-18 | ||
| US202163209317P | 2021-06-10 | 2021-06-10 | |
| US63/209,317 | 2021-06-10 | ||
| PCT/EP2021/068337 WO2022008374A1 (fr) | 2020-07-06 | 2021-07-02 | Systèmes et procédés d'analyse d'image basée sur l'intelligence artificielle pour la détection et la caractérisation de lésions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3163190A1 true CA3163190A1 (fr) | 2022-01-13 |
Family
ID=79552821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3163190A Pending CA3163190A1 (fr) | 2020-07-06 | 2021-07-02 | Systemes et procedes d'analyse d'image basee sur l'intelligence artificielle pour la detection et la caracterisation de lesions |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4176377A1 (fr) |
| JP (1) | JP2023532761A (fr) |
| KR (1) | KR20230050319A (fr) |
| CN (1) | CN116134479A (fr) |
| AU (1) | AU2021305935A1 (fr) |
| BR (1) | BR112022026642A2 (fr) |
| CA (1) | CA3163190A1 (fr) |
| MX (1) | MX2022016373A (fr) |
| TW (1) | TW202207241A (fr) |
| WO (1) | WO2022008374A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10340046B2 (en) | 2016-10-27 | 2019-07-02 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications |
| CN111095263A (zh) | 2017-06-26 | 2020-05-01 | 纽约州立大学研究基金会 | 用于虚拟胰造影术的系统、方法和计算机可访问介质 |
| WO2020144134A1 (fr) | 2019-01-07 | 2020-07-16 | Exini Diagnostics Ab | Systèmes et procédés de segmentation d'image de corps entier agnostique de plateforme |
| CA3134745A1 (fr) | 2019-04-24 | 2020-10-29 | Progenics Pharmaceuticals, Inc. | Systemes et procedes de reglage interactif de fenetrage d'intensite dans des images de medecine nucleaire |
| CA3136127A1 (fr) | 2019-04-24 | 2020-10-29 | Progenics Pharmaceuticals, Inc. | Systemes et procedes d'analyse automatisee et interactive d'images de scintigraphie osseuse pour la detection de metastases |
| US11900597B2 (en) | 2019-09-27 | 2024-02-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US11721428B2 (en) | 2020-07-06 | 2023-08-08 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
| TW202324443A (zh) | 2021-10-08 | 2023-06-16 | 瑞典商艾西尼診斷公司 | 用於自動鑑別及分類局部淋巴及遠處轉移中之病變的系統和方法 |
| CN114767268B (zh) * | 2022-03-31 | 2023-09-22 | 复旦大学附属眼耳鼻喉科医院 | 一种适用于内镜导航系统的解剖结构跟踪方法及装置 |
| CN114998249B (zh) * | 2022-05-30 | 2024-07-02 | 浙江大学 | 一种时空注意力机制约束的双示踪pet成像方法 |
| WO2023232067A1 (fr) * | 2022-05-31 | 2023-12-07 | Shanghai United Imaging Healthcare Co., Ltd. | Systèmes et procédés d'identification de région de lésion |
| US20230410985A1 (en) | 2022-06-08 | 2023-12-21 | Exini Diagnostics Ab | Systems and methods for assessing disease burden and progression |
| WO2024081727A2 (fr) * | 2022-10-11 | 2024-04-18 | The Regents Of The University Of Colorado, A Body Corporate | Identification de lésion basée sur l'apprentissage automatique adaptatif |
| CN116030284A (zh) * | 2023-01-31 | 2023-04-28 | 上海旦影医疗科技有限公司西安分公司 | 一种肿瘤参数测量方法、系统、装置及介质 |
| US20240285248A1 (en) | 2023-02-13 | 2024-08-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for predicting biochemical progression free survival in prostate cancer patients |
| US20240354940A1 (en) | 2023-04-07 | 2024-10-24 | Progenics Pharmaceuticals, Inc. | Systems and methods for facilitating lesion inspection and analysis |
| CN116309585B (zh) * | 2023-05-22 | 2023-08-22 | 山东大学 | 基于多任务学习的乳腺超声图像目标区域识别方法及系统 |
| CN117274244B (zh) * | 2023-11-17 | 2024-02-20 | 艾迪普科技股份有限公司 | 基于三维图像识别处理的医学成像检验方法、系统和介质 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7876938B2 (en) * | 2005-10-06 | 2011-01-25 | Siemens Medical Solutions Usa, Inc. | System and method for whole body landmark detection, segmentation and change quantification in digital images |
| US8562945B2 (en) | 2008-01-09 | 2013-10-22 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof |
| CA2732632C (fr) | 2008-08-01 | 2018-01-09 | The Johns Hopkins University | Agents de liaison au psma et ses utilisations |
| WO2010065902A2 (fr) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Complexes de technétium et de rhénium bis (hétéroaryle) et procédés d'utilisation de ceux-ci pour inhiber le psma |
| US10340046B2 (en) | 2016-10-27 | 2019-07-02 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications |
| WO2019136349A2 (fr) | 2018-01-08 | 2019-07-11 | Progenics Pharmaceuticals, Inc. | Systèmes et procédés de segmentation d'image basée sur un réseau neuronal rapide et détermination d'absorption d'un produit radiopharmaceutique |
| WO2020144134A1 (fr) | 2019-01-07 | 2020-07-16 | Exini Diagnostics Ab | Systèmes et procédés de segmentation d'image de corps entier agnostique de plateforme |
-
2021
- 2021-07-02 CA CA3163190A patent/CA3163190A1/fr active Pending
- 2021-07-02 JP JP2023500326A patent/JP2023532761A/ja active Pending
- 2021-07-02 AU AU2021305935A patent/AU2021305935A1/en active Pending
- 2021-07-02 CN CN202180050119.8A patent/CN116134479A/zh active Pending
- 2021-07-02 WO PCT/EP2021/068337 patent/WO2022008374A1/fr unknown
- 2021-07-02 TW TW110124481A patent/TW202207241A/zh unknown
- 2021-07-02 KR KR1020237003954A patent/KR20230050319A/ko unknown
- 2021-07-02 BR BR112022026642A patent/BR112022026642A2/pt unknown
- 2021-07-02 EP EP21739639.9A patent/EP4176377A1/fr active Pending
- 2021-07-02 MX MX2022016373A patent/MX2022016373A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4176377A1 (fr) | 2023-05-10 |
| KR20230050319A (ko) | 2023-04-14 |
| JP2023532761A (ja) | 2023-07-31 |
| MX2022016373A (es) | 2023-03-06 |
| WO2022008374A1 (fr) | 2022-01-13 |
| AU2021305935A1 (en) | 2023-02-02 |
| TW202207241A (zh) | 2022-02-16 |
| CN116134479A (zh) | 2023-05-16 |
| BR112022026642A2 (pt) | 2023-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3163190A1 (fr) | Systemes et procedes d'analyse d'image basee sur l'intelligence artificielle pour la detection et la caracterisation de lesions | |
| US11941817B2 (en) | Systems and methods for platform agnostic whole body image segmentation | |
| TWI835768B (zh) | 用於基於神經網路之快速影像分段及放射性藥品之攝取的測定之系統及方法 | |
| US11721428B2 (en) | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions | |
| JP7561140B2 (ja) | 転移を検出するための骨スキャン画像の自動化された対話型の分析のためのシステムおよび方法 | |
| US10973486B2 (en) | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination | |
| US11321844B2 (en) | Systems and methods for deep-learning-based segmentation of composite images | |
| US20230351586A1 (en) | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions | |
| US20240354940A1 (en) | Systems and methods for facilitating lesion inspection and analysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220527 |
|
| EEER | Examination request |
Effective date: 20220527 |
|
| EEER | Examination request |
Effective date: 20220527 |
|
| EEER | Examination request |
Effective date: 20220527 |
|
| EEER | Examination request |
Effective date: 20220527 |
|
| EEER | Examination request |
Effective date: 20220527 |
|
| EEER | Examination request |
Effective date: 20220527 |
|
| EEER | Examination request |
Effective date: 20220527 |